World Health Organization Issues Warning Over Critical Lack of Obesity Injections
Less than a tenth of people eligible to benefit from obesity jabs such as Wegovy can access them, states the global health agency as it publishes its initial recommendations on the therapies.
Given in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is advocating for more widespread and fairer access to this class of drugs.
Per projections, over two billion are projected to be living with obesity by 2030 without intervention.
"Our latest guidance acknowledges that excess weight is a chronic disease that can be treated with holistic and continuous care," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are significant obstacles to universal access to the injections that can assist patients in reducing substantial body mass, explains the organization.
Skinny Jab Supply Crisis
Even in the present most favorable scenario, the production of GLP-1 therapies might only reach approximately 100 million people – less than 10% of those who need them, according to the WHO.
The guideline calls on governments and firms to widen access, by measures including licensing agreements.
A patent on the active ingredient – the core component of Novo Nordisk's Wegovy – is set to lapse in multiple nations in 2026.
The Way Weight-Loss Jabs Function
The injections mimick a biological compound to slow digestion, suppress the appetite and increase satiety so users consume fewer calories.
People usually start to lose weight after several weeks of beginning the weekly injections.
Research points to patients may see weight return after a year of halting the medication, as their typical appetite resume.
To be carrying excess weight raises your chance for experiencing health problems, including diabetes, cardiovascular issues, stroke, and some cancers.
Excess weight affects people in countries worldwide and was responsible for millions of fatalities worldwide in 2024, according to the health agency.